Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?

References

• Holford NH, Buclin T. Safe and effective variability-a criterion for dose individualization. Ther Drug Monit. 2012;34(5):565–568.
   PubMed Web of Science ®Google Scholar
• Spence JD. A single fixed-dose combination for all patients is bad medicine. Can J Cardiol. 2014;30(5):513–516.
   PubMed Web of Science ®Google Scholar
• Platt DR. Individualization of drug dosage regimens. Clin Lab Med. 1987;7(2):289–299.
   PubMed Web of Science ®Google Scholar
• Dideberg V, Segers K, Koopmansch B, et al. Pharmacogenomics and personalized medicine: towards a systematic genomic screening? Rev Med Liege. 2015;70(5–6):251–256.
   PubMedGoogle Scholar
• Lesko LJ, Schmidt S. Individualization of drug therapy: history, present state, and opportunities for the future. Clin Pharmacol Ther. 2012;92(4):458–466.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Tsai WC, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):e16.
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Hollak CE, Cox TM, et al. Rare diseases and effective treatments: are we delivering? Lancet. 2015;385(9970):750–752.
   PubMed Web of Science ®Google Scholar
• Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
   PubMed Web of Science ®Google Scholar
• AEMPS - centro de información online de medicamentos de la AEMPS (CIMA) - buscador principal [homepage on the Internet]. [cited 2015 May 23]. Available from: http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=detalleForm
   Google Scholar
• KDIGO Board Members. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:136–150.
   Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Eechocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–1463.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Ramaswami U, Barba Romero MA, et al. Age adjusting severity scores for Anderson-Fabry disease. Mol Genet Metab. 2010;101(2–3):219–227.
   PubMed Web of Science ®Google Scholar
• Gillon R. Medical ethics: four principles plus attention to scope. BMJ. 1994;309(6948):184–188.
   PubMed Web of Science ®Google Scholar
• Isaacs D. Ethical dilemmas about orphan drugs for orphan diseases. J Paediatr Child Health. 2014;50(4):249–250.
   PubMed Web of Science ®Google Scholar
• Rombach SM, Smid BE, Bouwman MG, et al. Long term enzyme replacement therapy for fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.
   PubMed Web of Science ®Google Scholar
• Rombach SM, Hollak CE, Linthorst GE, et al. Cost-effectiveness of enzyme replacement therapy for fabry disease. Orphanet J Rare Dis. 2013;8:29.
   PubMed Web of Science ®Google Scholar
• Germain DP. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy. Clin Ther. 2007;29(Suppl A):S17–S18.
   PubMed Web of Science ®Google Scholar
• Mehta A. Fabry disease–whom to treat and when. Clin Ther. 2008;30(Suppl B):S43–S44.
   PubMed Web of Science ®Google Scholar
• Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of fabry disease. Proc Natl Acad Sci U S A. 2008;105(8):2812–2817.
   PubMed Web of Science ®Google Scholar
• Germain P, Roul G, Kastler B, et al. Inter-study variability in left ventricular mass measurement. comparison between M-mode echography and MRI. Eur Heart J. 1992;13(8):1011–1019.
   PubMed Web of Science ®Google Scholar
• Ladipo GO, Dunn FG, Pringle TH, et al. Serial measurements of left ventricular dimensions by echocardiography. assessment of week-to-week, inter- and intraobserver variability in normal subjects and patients with valvular heart disease. Br Heart J. 1980;44(3):284–289.
   PubMedGoogle Scholar
• Anastasakis A, Papatheodorou E, Steriotis AK. Fabry disease and cardiovascular involvement. Curr Pharm Des. 2013;19(33):5997–6008.
   PubMed Web of Science ®Google Scholar
• Germain DP, Weidemann F, Abiose A, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the fabry registry. Genet Med. 2013;15(12):958–965.
   PubMed Web of Science ®Google Scholar
• Pieroni M, Camporeale A, Della Bona R, et al. Progression of fabry cardiomyopathy despite enzyme replacement therapy. Circulation. 2013;128(15):1687–1688.
   PubMed Web of Science ®Google Scholar
• Smid BE, van der Tol L, Cecchi F, et al. Uncertain diagnosis of fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177(2):400–408.
   PubMed Web of Science ®Google Scholar
• Talbot AS, Lewis NT, Nicholls KM. Cardiovascular outcomes in fabry disease are linked to severity of chronic kidney disease. Heart. 2015;101(4):287–293.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Ertl G, Wanner C, et al. The fabry cardiomyopathy - diagnostic approach and current treatment. Curr Pharm Des. 2015;21(4):473–478.
   PubMed Web of Science ®Google Scholar
• Sanchez-Nino MD, Sanz AB, Carrasco S, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for fabry nephropathy. Nephrol Dial Transplant. 2011;26(6):1797–1802.
   PubMed Web of Science ®Google Scholar
• Waldek S, Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of fabry nephropathy? BMC Nephrol. 2014;15:72.
   PubMed Web of Science ®Google Scholar
• Warnock DG, Ortiz A, Mauer M, et al. Renal outcomes of agalsidase beta treatment for fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27(3):1042–1049.
   PubMed Web of Science ®Google Scholar
• Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European renal best practice. Nephrol Dial Transplant. 2013;28(3):505–517.
   PubMed Web of Science ®Google Scholar
• Basic-Jukic N, Kes P, Coric M, et al. Renal complications of fabry disease. Curr Pharm Des. 2013;19(33):6046–6050.
   PubMed Web of Science ®Google Scholar
• Becherucci F, Romagnani P. When foots come first: early signs of podocyte injury in fabry nephropathy without proteinuria. Nephron. 2015;129(1):3–5.
   PubMed Web of Science ®Google Scholar
• Rombach SM, Smid BE, Linthorst GE, et al. Natural course of fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014;37(3):341–352.
   PubMed Web of Science ®Google Scholar
• West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in fabry disease. J Am Soc Nephrol. 2009;20(5):1132–1139.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Kramer J, Duning T, et al. Patients with fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol. 2014;25(4):837–849.
   PubMed Web of Science ®Google Scholar
• Lohle M, Hughes D, Milligan A, et al. Clinical prodromes of neurodegeneration in anderson-fabry disease. Neurology. 2015;84(14):1454–1464.
   PubMed Web of Science ®Google Scholar
• Mendioroz M, Fernandez-Cadenas I, Montaner J. Neurological manifestations of fabry disease. Rev Neurol. 2006;43(12):739–745.
   PubMed Web of Science ®Google Scholar
• Fellgiebel A, Gartenschlager M, Wildberger K, et al. Enzyme replacement therapy stabilized white matter lesion progression in fabry disease. Cerebrovasc Dis. 2014;38(6):448–456.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wyatt KM, Henley W, et al. Long-term effectiveness of enzyme replacement therapy in fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):969–978.
   PubMed Web of Science ®Google Scholar
• Watt T, Burlina AP, Cazzorla C, et al. Agalsidase beta treatment is associated with improved quality of life in patients with fabry disease: findings from the fabry registry. Genet Med. 2010;12(11):703–712.
   PubMed Web of Science ®Google Scholar
• van Breemen MJ, Rombach SM, Dekker N, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812(1):70–76.
   PubMed Web of Science ®Google Scholar
• Lubanda JC, Anijalg E, Bzduch V, et al. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with fabry disease. Genet Med. 2009;11(4):256–264.
   PubMed Web of Science ®Google Scholar
• Casassus B. Europe urged to take action on drug shortages. Lancet. 2015;385(9975):1279–1280.
   PubMed Web of Science ®Google Scholar
• Dill S, Ahn J. Drug shortages in developed countries–reasons, therapeutic consequences, and handling. Eur J Clin Pharmacol. 2014;70(12):1405–1412.
   PubMed Web of Science ®Google Scholar
• Sirrs S. The fabrazyme shortage–a call to action for metabolic physicians. Mol Genet Metab. 2011;102(1):4–5.
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Germain DP, Hollak CE, et al. Expert opinion on temporary treatment recommendations for fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab. 2011;102(1):99–102.
   PubMed Web of Science ®Google Scholar
• Concolino D, Degennaro E, Parini R, et al. Delphi consensus on the current clinical and therapeutic knowledge on anderson-fabry disease. Eur J Intern Med. 2014;25(8):751–756.
   PubMed Web of Science ®Google Scholar
• Consenso de Medicos de AADELFA y GADYTEF, Neumann P, Antongiovanni N, et al. Guidelines for diagnosis, monitoring and treatment of fabry disease. Medicina (B Aires) 2013;73(5):482–494.
   PubMed Web of Science ®Google Scholar
• Garcia de Lorenzo A, en nombre del grupo de enfermedad de FABRY-GETER. Consensus for the study and treatment of fabry disease. GETER foundation. Med Clin (Barc). 2011;137(4):178–183.
   PubMed Web of Science ®Google Scholar
• Giraldo P, Grupo de Trabajo de las Guias de Actuacion. Guidelines for type 1 gaucher’s disease. Med Clin (Barc). 2011;137(Suppl 1):55–60.
   PubMedGoogle Scholar
• Giraldo P, Latre P. Current treatment for gaucher’s disease and new prospects. Med Clin (Barc). 2011;137(Suppl 1):50–54.
   PubMedGoogle Scholar
• Campillo-Artero C, del Llano J, Poveda JL. Risk sharing agreements: with orphan drugs? Farm Hosp. 2012;36(6):455–463.
   PubMedGoogle Scholar